Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.39M rose 734.3% year over year, ahead of the -86.9% change in trailing-twelve-month other income / expenses.
Context
- Other income / expenses amounted to 2.7% of revenue in FY2025, down 121.6 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +734.3% holds above the trailing-twelve-month pace of -86.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (894K) USD
- Year-over-year change
- -127.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (894K) | -127.3% |
| FY2024 | 2024-12-31 | 3.28M | +37.3% |
| FY2023 | 2023-12-31 | 2.39M | +350.9% |
| FY2022 | 2022-12-31 | (951K) | +21.7% |
| FY2021 | 2021-12-31 | (1.22M) | — |
Other Income / Expenses vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -86.9% is the 7th highest of 11, against a peer median of -44.5%.
- Other income / expenses amounts to 1.0% of revenue for OBIO, versus a peer median of 38.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.75M USD | +12.2% | +85.7% | — | |
| LTM Mar 2026 | $6.34M USD | -47.8% | -14.5% | 37.9% | |
| LTM Mar 2026 | $5.52M USD | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $4.17M USD | -16.4% | -23.0% | 7.5% | |
| LTM Mar 2026 | $2.85M USD | -27.9% | +11.8% | 1268.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $2.76M USD | +155.6% | — | — |
| LTM Mar 2026 | $325K USD | -86.9% | — | 1.0% | |
| LTM Mar 2026 | -$1.51M USD | -146.9% | +2.8% | 2.2% | |
| LTM Mar 2026 | -$2.06M USD | -113.1% | — | 18.4% | |
| LTM Mar 2026 | -$5.41M USD | -104.4% | — | 9176.3% | |
| FY2025 | -€211.38M EUR | -144.8% | — | 4715.1% | |
| Peer median (excluding OBIO) | — | -44.5% | +7.3% | 38.9% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | (782K) | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | 199K | 322K | 186K | 204K | 190K |
| Gross Profit | (981K) | 3.21M | 2.57M | 2.43M | 33.29M |
| Gross Margin | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| Research & Development | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| Selling, General & Admin | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| Operating Expenses | 20.82M | 35.87M | 54.08M | 66.74M | 85.1M |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| EBITDA | (21.91M) | (33.39M) | (48.83M) | (60.72M) | (51.23M) |
| EBITDA Margin | 2801.3% | -945.0% | -1769.3% | -2301.6% | -153.0% |
| Operating Income | (21.8M) | (32.66M) | (51.51M) | (64.3M) | (51.81M) |
| Operating Margin | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Interest Income | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 927K | 0 | 0 | 0 | 1.15M |
| Other Income / Expenses | (1.22M) | (951K) | 2.39M | 3.28M | (894K) |
| Income Before Tax | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Pre-Tax Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Net Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (Basic) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| EPS (Diluted) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| Weighted Avg Shares | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
| Weighted Avg Shares (Diluted) | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.